title: Targeted human serum albumin nanoparticles for specific uptake in EGFR-Expressing colon carcinoma cells.
abstract: The specific application and transport of drugs into malignant tissue is a critical point during diagnosis and therapy. Nanoparticles are known as excellent drug carrier systems and offer the possibility of surface modification with targeting ligands, leading to a specific accumulation in the targeted tissue. First, the specificity of such a carrier system has to be proven. In this study, cetuximab-modified nanoparticles based on biodegradable human serum albumin (HSA) are investigated regarding their cellular binding and intracellular accumulation. Different EGFR-expressing colon carcinoma cells were used to test possible cytotoxic potential, specific binding and intracellular accumulation. A specific accumulation targeting the EGFR could be shown. These results emphasize that cetuximab-modified HSA-nanoparticles are a promising carrier system for later drug transport. To our knowledge, this is the first study investigating the specific accumulation of HSA nanoparticles into different EGFR-expressing colon carcinoma cells.
  
  
  BACKGROUND
  In this study, cetuximab-modified nanoparticles based on human serum albumin (HSA) are investigated regarding their cellular binding and intracellular accumulation. The results suggest that these nanoparticles are a promising carrier system for EGFR overexpressing colon carcinoma cells.
authors.affiliation: Department of Cell Biology and Applied Virology, Fraunhofer-Institute for Biomedical Engineering, St. Ingbert, Germany.
authors.forename: Karin
authors.initials: K
authors.lastname: Löw
authors.forename: Matthias
authors.initials: M
authors.lastname: Wacker
authors.forename: Sylvia
authors.initials: S
authors.lastname: Wagner
authors.forename: Klaus
authors.initials: K
authors.lastname: Langer
authors.forename: Hagen
authors.initials: H
authors.lastname: von Briesen
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000737:chemistry*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000737:chemistry* / Q000494:pharmacology; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D000068818:Cetuximab; D003110:Colonic Neoplasms / Q000378:metabolism*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006801:Humans; D053758:Nanoparticles / Q000008:administration & dosage / Q000737:chemistry*; D036103:Nanotechnology / Q000379:methods*; D012709:Serum Albumin / Q000737:chemistry*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D012709:Serum Albumin; D066246:ErbB Receptors; D000068818:Cetuximab